Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neuroscience Bulletin
Erschienen in: Neuroscience Bulletin 8/2021

01.08.2021 | Review

Hypothalamic-Pituitary-End-Organ Axes: Hormone Function in Female Patients with Major Depressive Disorder

verfasst von: Yuncheng Zhu, Xiaohui Wu, Rubai Zhou, Oliver Sie, Zhiang Niu, Fang Wang, Yiru Fang

Erschienen in: Neuroscience Bulletin | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Classic hypothalamic-pituitary-end-organ feedback loops – the hypothalamic-pituitary-adrenal axis (HPAA), hypothalamic-pituitary-thyroidal axis (HPTA), and hypothalamic-pituitary-gonadal axis (HPGA) – are associated with the neuroendocrine and immune systems in major depressive disorder (MDD). Female patients with MDD present with evident neuroendocrine and immunological changes. Glucocorticoid, thyroid hormone, and reproductive steroid levels fluctuate with menstrual cycles, which might lead to glucocorticoid receptor resistance, impairment of triiodothyronine conversion, and sex hormone secretion disorders. In this review, we summarize the independent and interactive functions of these three axes in female MDD patients. The similar molecular structure of steroids implies an interrelationship between the hypothalamic-pituitary-end-organ axes and the competitive inhibitory effects at the receptor level, especially when considering the HPAA and HPGA.
Literatur
1.
Lee EH, Han PL. Reciprocal interactions across and within multiple levels of monoamine and cortico-limbic systems in stress-induced depression: A systematic review. Neurosci Biobehav Rev 2019, 101: 13–31.PubMedCrossRef
2.
Liang X, Zhu Y, Fang Y. COVID-19 and post-traumatic stress disorder: A vicious circle involving immunosuppression. CNS Neurosci Ther 2020, 26: 876–878.PubMedCrossRef
3.
Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA 2007, 298: 1685–1687.PubMedCrossRef
4.
Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65: 732–741.PubMedPubMedCentralCrossRef
5.
Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci 2013, 14: 135–151.PubMedCrossRef
6.
Wang F, Jin J, Wang J, He R, Li K, Hu X. Association between olfactory function and inhibition of emotional competing distractors in major depressive disorder. Sci Rep 2020, 10: 6322.PubMedPubMedCentralCrossRef
7.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9: 46–56.PubMedPubMedCentralCrossRef
8.
Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 2009, 1179: 86–105.
9.
10.
Horowitz MA, Zunszain PA. Neuroimmune and neuroendocrine abnormalities in depression: two sides of the same coin. Ann N Y Acad Sci 2015, 1351: 68–79.PubMedCrossRef
11.
Bale TL. Neuroendocrine and immune influences on the CNS: it’s a matter of sex. Neuron 2009, 64: 13–16.PubMedCrossRef
12.
Zhu Y, Ji H, Tao L, Cai Q, Wang F, Ji W, et al. Functional status of hypothalamic–pituitary–thyroid and hypothalamic–pituitary–adrenal axes in hospitalized schizophrenics in Shanghai. Front Psychiatry 2020, 11: 65.PubMedPubMedCentralCrossRef
13.
Han Y, Ji H, Liu L, Zhu Y, Jiang X. The relationship of functional status of cortisol, testosterone, and parameters of metabolic syndrome in male schizophrenics. Biomed Res Int 2020, 2020: 9124520.PubMedPubMedCentralCrossRef
14.
15.
Chen X, Zheng X, Ding Z, Su Y, Wang S, Cui B, et al. Relationship of gender and age on thyroid hormone parameters in a large Chinese population. Arch Endocrinol Metab 2020, 64: 52–58.PubMed
16.
17.
Kudielka BM, Buske-Kirschbaum A, Hellhammer DH, Kirschbaum C. HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psychoneuroendocrinology 2004, 29: 83–98.PubMedCrossRef
18.
Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008, 31: 464–468.PubMedCrossRef
19.
Pariante CM. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann N Y Acad Sci 2009, 1179: 144–152.
20.
Burke HM, Davis MC, Otte C, Mohr DC. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology 2005, 30: 846–856.PubMedCrossRef
21.
Wang SS, Mu RH, Li CF, Dong SQ, Geng D, Liu Q, et al. microRNA-124 targets glucocorticoid receptor and is involved in depression-like behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2017, 79: 417–425.PubMedCrossRef
22.
Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49: 391–404.PubMedCrossRef
23.
Bekhbat M, Rowson SA, Neigh GN. Checks and balances: The glucocorticoid receptor and NFkB in good times and bad. Front Neuroendocrinol 2017, 46: 15–31.PubMedPubMedCentralCrossRef
24.
25.
Makhija K, Karunakaran S. The role of inflammatory cytokines on the aetiopathogenesis of depression. Aust N Z J Psychiatry 2013, 47: 828–839.PubMedCrossRef
26.
Niu Z, Yang L, Wu X, Zhu Y, Chen J, Fang Y. The relationship between neuroimmunity and bipolar disorder: Mechanism and translational application. Neurosci Bull 2019, 35: 595–607.PubMedPubMedCentralCrossRef
27.
Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci 2012, 1261: 55–63.PubMedPubMedCentralCrossRef
28.
Shelton MM, Schminkey DL, Groer MW. Relationships among prenatal depression, plasma cortisol, and inflammatory cytokines. Biol Res Nurs 2015, 17: 295–302.PubMedCrossRef
29.
30.
Tynan RJ, Naicker S, Hinwood M, Nalivaiko E, Buller KM, Pow DV, et al. Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav Immun 2010, 24: 1058–1068.PubMedCrossRef
31.
Blandino P Jr, Barnum CJ, Deak T. The involvement of norepinephrine and microglia in hypothalamic and splenic IL-1beta responses to stress. J Neuroimmunol 2006, 173: 87–95.PubMedCrossRef
32.
33.
Walker FR, Nilsson M, Jones K. Acute and chronic stress-induced disturbances of microglial plasticity, phenotype and function. Curr Drug Targets 2013, 14: 1262–1276.PubMedCrossRef
34.
Alt SR, Turner JD, Klok MD, Meijer OC, Lakke EA, Derijk RH, et al. Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed. Psychoneuroendocrinology 2010, 35: 544–556.PubMedCrossRef
35.
ter Heegde F, De Rijk RH, Vinkers CH. The brain mineralocorticoid receptor and stress resilience. Psychoneuroendocrinology 2015, 52: 92–110.PubMedCrossRef
36.
Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM Jr, et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry 2017, 22: 527–536.PubMedCrossRef
37.
Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003, 160: 1554–1565.PubMedCrossRef
38.
Anacker C, Zunszain PA, Carvalho LA, Pariante CM. The glucocorticoid receptor: pivot of depression and of antidepressant treatment?. Psychoneuroendocrinology 2011, 36: 415–425.PubMedPubMedCentralCrossRef
39.
Pochigaeva K, Druzhkova T, Yakovlev A, Onufriev M, Grishkina M, Chepelev A, et al. Hair cortisol as a marker of hypothalamic-pituitary-adrenal axis activity in female patients with major depressive disorder. Metab Brain Dis 2017, 32: 577–583.PubMedCrossRef
40.
Young EA, Veldhuis JD. Disordered adrenocorticotropin secretion in women with major depression. J Clin Endocrinol Metab 2006, 91: 1924–1928.PubMedCrossRef
41.
Rampp C, Eichelkraut A, Best J, Czamara D, Rex-Haffner M, Uhr M, et al. Sex-related differential response to dexamethasone in endocrine and immune measures in depressed in-patients and healthy controls. J Psychiatr Res 2018, 98: 107–115.PubMedCrossRef
42.
Roos LE, Beauchamp KG, Giuliano R, Zalewski M, Kim HK, Fisher PA. Children’s biological responsivity to acute stress predicts concurrent cognitive performance. Stress 2018, 21: 347–354.PubMedPubMedCentralCrossRef
43.
Wei J, Sun G, Zhao L, Yang X, Liu X, Lin D, et al. Analysis of hair cortisol level in first-episodic and recurrent female patients with depression compared to healthy controls. J Affect Disord 2015, 175: 299–302.PubMedCrossRef
44.
Kaess M, Whittle S, O’Brien-Simpson L, Allen NB, Simmons JG. Childhood maltreatment, pituitary volume and adolescent hypothalamic-pituitary-adrenal axis - Evidence for a maltreatment-related attenuation. Psychoneuroendocrinology 2018, 98: 39–45.PubMedCrossRef
45.
Zhu Y, Wu Z, Sie O, Cai Y, Huang J, Liu H, et al. Causes of drug discontinuation in patients with major depressive disorder in China. Prog Neuropsychopharmacol Biol Psychiatry 2020, 96: 109755.PubMedCrossRef
46.
Fischer S, Ehlert U. Hypothalamic-pituitary-thyroid (HPT) axis functioning in anxiety disorders. A systematic review. Depress Anxiety 2018, 35: 98–110.PubMedCrossRef
47.
Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015, 29: 459–525.PubMedCrossRef
48.
Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry 2008, 63: 1127–1134.PubMedCrossRef
49.
Tundo A, de Filippis R, Proietti L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J Psychiatry 2015, 5: 330–341.PubMedPubMedCentralCrossRef
50.
Dold M, Bartova L, Mendlewicz J, Souery D, Serretti A, Porcelli S, et al. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatr Scand 2018, 137: 401–412.PubMedPubMedCentralCrossRef
51.
Martin SS, Daya N, Lutsey PL, Matsushita K, Fretz A, McEvoy JW, et al. Thyroid function, cardiovascular risk factors, and incident atherosclerotic cardiovascular disease: The atherosclerosis risk in communities (ARIC) study. J Clin Endocrinol Metab 2017, 102: 3306–3315.PubMedPubMedCentralCrossRef
52.
Hage MP, Azar ST. The link between thyroid function and depression. J Thyroid Res 2012, 2012: 590648.PubMedCrossRef
53.
Giynas Ayhan M, Uguz F, Askin R, Gonen MS. The prevalence of depression and anxiety disorders in patients with euthyroid Hashimoto’s thyroiditis: a comparative study. Gen Hosp Psychiatry 2014, 36: 95–98.PubMedCrossRef
54.
Saidi S, Iliani Jaafar SN, Daud A, Musa R, Nik Ahmad NNF. Relationship between levels of thyroid stimulating hormone, age, and gender, with symptoms of depression among patients with thyroid disorders as measured by the Depression Anxiety Stress Scale 21 (DASS-21). Enferm Clin 2018, 28(Suppl 1): 180–183.CrossRef
55.
Gietka-Czernel M. The thyroid gland in postmenopausal women: physiology and diseases. Prz Menopauzalny 2017, 16: 33–37.PubMedPubMedCentral
56.
Gaberscek S, Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev Clin Immunol 2011, 7: 697–706; quiz 707.
57.
Pedersen C, Leserman J, Garcia N, Stansbury M, Meltzer-Brody S, Johnson J. Late pregnancy thyroid-binding globulin predicts perinatal depression. Psychoneuroendocrinology 2016, 65: 84–93.PubMedCrossRef
58.
Kurioka H, Takahashi K, Miyazaki K. Maternal thyroid function during pregnancy and puerperal period. Endocr J 2005, 52: 587–591.PubMedCrossRef
59.
Jonklaas J, Kahric-Janicic N, Soldin OP, Soldin SJ. Correlations of free thyroid hormones measured by tandem mass spectrometry and immunoassay with thyroid-stimulating hormone across 4 patient populations. Clin Chem 2009, 55: 1380–1388.PubMedPubMedCentralCrossRef
60.
Pedersen CA, Johnson JL, Silva S, Bunevicius R, Meltzer-Brody S, Hamer RM, et al. Antenatal thyroid correlates of postpartum depression. Psychoneuroendocrinology 2007, 32: 235–245.PubMedCrossRef
61.
Rubinow DR, Schmidt PJ. Sex differences and the neurobiology of affective disorders. Neuropsychopharmacology 2019, 44: 111–128.PubMedCrossRef
62.
Barut MU, Coksuer H, Sak S, Bozkurt M, Agacayak E, Hamurcu U, et al. Evaluation of sexual function in women with hypogonadotropic hypogonadism using the female sexual function index (FSFI) and the beck depression inventory (BDI). Med Sci Monit 2018, 24: 5610–5618.PubMedPubMedCentralCrossRef
63.
Sakinci M, Ercan CM, Olgan S, Coksuer H, Karasahin KE, Kuru O. Comparative analysis of copper intrauterine device impact on female sexual dysfunction subtypes. Taiwan J Obstet Gynecol 2016, 55: 460–461.PubMedCrossRef
64.
Basson R, Rees P, Wang R, Montejo AL, Incrocci L. Sexual function in chronic illness. J Sex Med 2010, 7: 374–388.PubMedCrossRef
65.
Berman JR, Bassuk J. Physiology and pathophysiology of female sexual function and dysfunction. World J Urol 2002, 20: 111–118.PubMedCrossRef
66.
Atis G, Dalkilinc A, Altuntas Y, Atis A, Caskurlu T, Ergenekon E. Sexual dysfunction in women with clinical hypothyroidism and subclinical hypothyroidism. J Sex Med 2010, 7: 2583–2590.PubMedCrossRef
67.
Bhasin S, Enzlin P, Coviello A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet 2007, 369: 597–611.PubMedCrossRef
68.
Goldstein JM, Hale T, Foster SL, Tobet SA, Handa RJ. Sex differences in major depression and comorbidity of cardiometabolic disorders: impact of prenatal stress and immune exposures. Neuropsychopharmacology 2019, 44: 59–70.PubMedCrossRef
69.
70.
Santoro N. Perimenopause: From research to practice. J Womens Health (Larchmt) 2016, 25: 332–339.CrossRef
71.
Naheed B, Kuiper JH, Uthman OA, O'Mahony F, O'Brien PM. Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome. Cochrane Database Syst Rev 2017, 3: CD010503.
72.
Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician 2011, 84: 918–924.PubMed
73.
Carrier J, Semba K, Deurveilher S, Drogos L, Cyr-Cronier J, Lord C, et al. Sex differences in age-related changes in the sleep-wake cycle. Front Neuroendocrinol 2017, 47: 66–85.PubMedCrossRef
74.
Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS Spectr 2015, 20: 48–59.PubMedCrossRef
75.
Gordon JL, Girdler SS, Meltzer-Brody SE, Stika CS, Thurston RC, Clark CT, et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am J Psychiatry 2015, 172: 227–236.PubMedPubMedCentralCrossRef
76.
77.
Studd JW. A guide to the treatment of depression in women by estrogens. Climacteric 2011, 14: 637–642.PubMedCrossRef
78.
Whedon JM, KizhakkeVeettil A, Rugo NA, Kieffer KA. Bioidentical estrogen for menopausal depressive symptoms: A systematic review and meta-analysis. J Womens Health (Larchmt) 2017, 26: 18–28.CrossRef
79.
Wang F, Wu X, Gao J, Li Y, Zhu Y, Fang Y. The relationship of olfactory function and clinical traits in major depressive disorder. Behav Brain Res 2020, 386: 112594.PubMedCrossRef
80.
Rodgers S, Vandeleur CL, Ajdacic-Gross V, Aleksandrowicz AA, Strippoli MF, Castelao E, et al. Tracing the associations between sex, the atypical and the combined atypical-melancholic depression subtypes: A path analysis. J Affect Disord 2016, 190: 807–818.PubMedCrossRef
81.
Herzog DP, Wegener G, Lieb K, Muller MB, Treccani G. Decoding the mechanism of action of rapid-acting antidepressant treatment strategies: Does gender matter?. Int J Mol Sci 2019, 20: 949.PubMedCentralCrossRef
82.
Skovlund CW, Morch LS, Kessing LV, Lidegaard O. Association of hormonal contraception with depression. JAMA Psychiatry 2016, 73: 1154–1162.PubMedCrossRef
83.
Sharma V, Al-Farayedhi M, Doobay M, Baczynski C. Should all women with postpartum depression be screened for bipolar disorder?. Med Hypotheses 2018, 118: 26–28.PubMedCrossRef
84.
Studd J. Spotlight on severe premenstrual syndrome and bipolar disorder: a frequent tragic confusion. Climacteric 2011, 14: 602.PubMed
85.
Sharma V, Burt VK, Ritchie HL. Assessment and treatment of bipolar II postpartum depression: a review. J Affect Disord 2010, 125: 18–26.PubMedCrossRef
86.
Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci 2015, 9: 37.PubMedPubMedCentralCrossRef
87.
Frieder A, Fersh M, Hainline R, Deligiannidis KM. Pharmacotherapy of postpartum depression: Current approaches and novel drug development. CNS Drugs 2019, 33: 265–282.PubMedPubMedCentralCrossRef
88.
Patte-Mensah C, Meyer L, Taleb O, Mensah-Nyagan AG. Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain. Prog Neurobiol 2014, 113: 70–78.PubMedCrossRef
89.
Andreen L, Nyberg S, Turkmen S, van Wingen G, Fernandez G, Backstrom T. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009, 34: 1121–1132.PubMedCrossRef
90.
Baka J, Csakvari E, Huzian O, Dobos N, Siklos L, Leranth C, et al. Stress induces equivalent remodeling of hippocampal spine synapses in a simulated postpartum environment and in a female rat model of major depression. Neuroscience 2017, 343: 384–397.PubMedCrossRef
91.
Schule C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs?. Neuroscience 2011, 191: 55–77.PubMedCrossRef
92.
Brown SB, MacLatchy DL, Hara TJ, Eales JG. Effects of cortisol on aspects of 3,5,3’-triiodo-L-thyronine metabolism in rainbow trout (Oncorhynchus mykiss). Gen Comp Endocrinol 1991, 81: 207–216.PubMedCrossRef
93.
Sahoo M, Subho C. Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates. Psychoneuroendocrinology 2007, 32: 210; author reply 211–212.
94.
Evans J, Sun Y, McGregor A, Connor B. Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. Neuropharmacology 2012, 63: 1315–1326.PubMedCrossRef
95.
Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A. Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression. J Clin Psychopharmacol 2017, 37: 505–511.PubMedPubMedCentralCrossRef
96.
Mason BL, Pariante CM. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News Perspect 2006, 19: 603–608.PubMedCrossRef
97.
DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006, 60: 1343–1349.PubMedCrossRef
98.
Soria V, Gonzalez-Rodriguez A, Huerta-Ramos E, Usall J, Cobo J, Bioque M, et al. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis. Psychoneuroendocrinology 2018, 93: 8–19.PubMedCrossRef
99.
Bjorn I, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom G, Backstrom T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 2003, 88: 2026–2030.PubMedCrossRef
100.
Khorsand I, Kashef R, Ghazanfarpour M, Mansouri E, Dashti S, Khadivzadeh T. The beneficial and adverse effects of raloxifene in menopausal women: A mini review. J Menopausal Med 2018, 24: 183–187.PubMedPubMedCentralCrossRef
101.
Hoyer J, Burmann I, Kieseler ML, Vollrath F, Hellrung L, Arelin K, et al. Menstrual cycle phase modulates emotional conflict processing in women with and without premenstrual syndrome (PMS) - a pilot study. Plos One 2013, 8: e59780.PubMedPubMedCentralCrossRef
102.
Wolfram M, Bellingrath S, Kudielka BM. The cortisol awakening response (CAR) across the female menstrual cycle. Psychoneuroendocrinology 2011, 36: 905–912.PubMedCrossRef
103.
Kiesner J, Granger DA. A lack of consistent evidence for cortisol dysregulation in premenstrual syndrome/premenstrual dysphoric disorder. Psychoneuroendocrinology 2016, 65: 149–164.PubMedCrossRef
Metadaten
Titel
Hypothalamic-Pituitary-End-Organ Axes: Hormone Function in Female Patients with Major Depressive Disorder
verfasst von
Yuncheng Zhu
Xiaohui Wu
Rubai Zhou
Oliver Sie
Zhiang Niu
Fang Wang
Yiru Fang
Publikationsdatum
01.08.2021
Verlag
Springer Singapore
Erschienen in
Neuroscience Bulletin / Ausgabe 8/2021
Print ISSN: 1673-7067
Elektronische ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-021-00689-6

Weitere Artikel der Ausgabe 8/2021

Neuroscience Bulletin 8/2021 Zur Ausgabe

Letter to the Editor

Mitochondrial Events Determine the Status of Hippocampal Cells in the Post-Ischemic Period

Original Article

The Amygdala Responds Rapidly to Flashes Linked to Direct Retinal Innervation: A Flash-evoked Potential Study Across Cortical and Subcortical Visual Pathways

Original Article

An Intronic Variant of CHD7 Identified in Autism Patients Interferes with Neuronal Differentiation and Development

RESEARCH HIGHLIGHT

A Temporal Precision Approach for Deep Transcranial Optogenetics with Non-invasive Surgery

Review

Emerging Role of PD-1 in the Central Nervous System and Brain Diseases

Letter to the Editor

Inhibition of PI4KIIIα as a Novel Potential Approach for Gaucher Disease Treatment

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise